Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29140999 | 0.88 | MTNR1A (0.68) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL830122 | 0.86 | MTNR1A (0.67) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL8534816 | 0.85 | MTNR1A (0.69) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL31392475 | 0.83 | MTNR1A (0.70) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL10856546 | 0.83 | MTNR1A (0.70) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL3327762 | 0.83 | MTNR1A (0.70) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL8610416 | 0.80 | MTNR1A (0.59) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL8610419 | 0.79 | MTNR1A (0.58) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL4108535 | 0.79 | MTNR1A (0.65) | MTNR1ACNR2MTNR1BHTR2CHTR2B | |
| SCHEMBL31613073 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| CN-101643431-B | New process for synthesizing agomelatine | SERVIER LAB | 2013-05-15 | — | — | CN | disclosed |
| US-8143449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-2151429-B1 | Process for the preparation of agomelatin | SERVIER LAB (FR) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015746-A1 | NOVEL METHOD FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036163-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2151429-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151429-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036163-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | MTNR1A 331/4885CNR2 1335/4885MTNR1B 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.